VFA
TVTX icon

Virtus Fund Advisers’s Travere Therapeutics TVTX Stock Holding History

Virtus Fund Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$933K Buy
+44,297
New +$1.01M 0.01% 304
2014
Q3 		– Sell
-1,815
Closed -$21K – 1893
2014
Q2 		$21K Buy
+1,815
New +$24.6K ﹤0.01% 2410

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Virtus Fund Advisers's TVTX Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Travere Therapeutics (TVTX) in Q4 2017: 44,297 shares worth $933K. The stake represents 0.01% of the portfolio and ranks #304 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in TVTX as recently as Q2 2014.

Virtus Fund Advisers first reported a position in TVTX in Q2 2014 and has held it in 2 quarters since. 120 funds tracked by Wall St. Rank hold TVTX as of Q4 2017.

  • Virtus Fund Advisers held 44,297 shares of Travere Therapeutics worth $933K as of Q4 2017.
  • Travere Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Travere Therapeutics made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #304 holding.
  • Virtus Fund Advisers first reported a position in Travere Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 120 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.